Hostname: page-component-5f7774ffb-mstw7 Total loading time: 0 Render date: 2026-02-22T03:34:17.270Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Hunt et al. “A Retrospective Evaluation of Ocrelizumab and Rituximab Discontinuation in a Real-World Patient Cohort”

Published online by Cambridge University Press:  20 February 2026

Caitlin Jackson-Tarlton Open the ORCID record for Caitlin Jackson-Tarlton [Opens in a new window]
Caitlin Jackson-Tarlton*
Affiliation:
Dalhousie University, Halifax, Nova Scotia, Canada
*
Email: caitlin.tarlton@dal.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Freedman, MS, Clift, F, Devonshire, V, et al. First-line use of higher-efficacy disease-modifying therapies in multiple sclerosis: canadian consensus recommendations. Can J Neurol Sci. 2025;9: 1–10. DOI: 10.1017/cjn.2025.10342.Google Scholar
Hauser, SL, Kappos, L, Arnold, DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95:e1854–e1867. DOI: 10.1212/WNL.0000000000010376.10.1212/WNL.0000000000010376CrossRefGoogle ScholarPubMed
Hunt, D, Chu, N, Kuipers, D, et al. A retrospective evaluation of ocrelizumab and rituximab discontinuation in a real-world patient cohort. Can J Neurol Sci. DOI: 10.1017/cjn.2025.10520.10.1017/cjn.2025.10520CrossRefGoogle Scholar
Dunn, N, Juto, A, Ryner, M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24:1224–33. DOI: 10.1177/1352458517720044.10.1177/1352458517720044CrossRefGoogle ScholarPubMed
Laurson-Doube, J, Helme, A, Nonino, F, Piggott, T, Rijke, N, Saylor, D. WHO considers multiple sclerosis treatments essential. Lancet Neurol. 2024;23:140. DOI: 10.1016/S1474-4422(23)00505-7.10.1016/S1474-4422(23)00505-7CrossRefGoogle ScholarPubMed
Hogenboom, L, van Kempen, ZLE, Kalincik, T, Bar-Or, A, Killestein, J. A personalized approach for anti-CD20 therapies in multiple sclerosis. Mult Scler Relat Disord. 2024;91:105851. DOI: 10.1016/j.msard.2024.105851.10.1016/j.msard.2024.105851CrossRefGoogle ScholarPubMed